Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/11182
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3460]
Metadata
Show full item record
EVALUATION OF TWO LINE PROBE ASSAYS FOR RAPID DETECTION OF MYCOBACTERIUM TUBERCULOSIS, TUBERCULOSIS (TB) DRUG RESISTANCE, AND NON-TB MYCOBACTERIA IN HIV-INFECTED INDIVIDUALS WITH SUSPECTED TB
Author
Affilliation
University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, CA, United States of America
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, United States of America
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, United States of America
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil
University of the Witwatersrand. Clinical Laboratory Services and School of Pathology. Johannesburg, South Africa
University of Nebraska Medical Center. Division of Infectious Diseases. Omaha, NE, United States of America
Montgomery County Health Department. Silver Spring, MD, United States of America
Asociación Civil Impacta Salud y Educación. Lima, Peru
University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, CA, United States of America
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil
University of the Witwatersrand. Johannesburg. Faculty of Health Sciences. Clinical HIV Research Unit. South Africah / Right to Care. Johannesburg, South Africa
University of the Witwatersrand. Johannesburg. Faculty of Health Sciences. Clinical HIV Research Unit. South Africah / Right to Care. Johannesburg, South Africa
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, United States of America
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, United States of America
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil
University of the Witwatersrand. Clinical Laboratory Services and School of Pathology. Johannesburg, South Africa
University of Nebraska Medical Center. Division of Infectious Diseases. Omaha, NE, United States of America
Montgomery County Health Department. Silver Spring, MD, United States of America
Asociación Civil Impacta Salud y Educación. Lima, Peru
University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, CA, United States of America
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil
University of the Witwatersrand. Johannesburg. Faculty of Health Sciences. Clinical HIV Research Unit. South Africah / Right to Care. Johannesburg, South Africa
University of the Witwatersrand. Johannesburg. Faculty of Health Sciences. Clinical HIV Research Unit. South Africah / Right to Care. Johannesburg, South Africa
Abstract
Limited performance data from line probe assays (LPAs), nucleic acid tests used for the rapid diagnosis of tuberculosis (TB), nontuberculosis mycobacteria (NTM), and Mycobacterium tuberculosis drug resistance are available for HIV-infected individuals, in whom paucibacillary TB is common. In this study, the strategy of testing sputum with GenoType MTBDRplus (MTBDR-Plus) and GenoType Direct LPA (Direct LPA) was compared to a gold standard of one mycobacterial growth indicator tube (MGIT) liquid culture. HIV-positive (HIV+) individuals with suspected TB from southern Africa and South America with <7 days of TB treatment had 1 sputum specimen tested with Direct LPA, MTBDR-Plus LPA, smear microscopy, MGIT, biochemical identification of mycobacterial species, and culture-based drug-susceptibility testing (DST). Of 639 participants, 59.3% were MGIT M. tuberculosis culture positive, of which 276 (72.8%) were acid-fast bacillus (AFB) smear positive. MTBDR-Plus had a sensitivity of 81.0% and a specificity of 100%, with sensitivities of 44.1% in AFB smear-negative versus 94.6% in AFB smear-positive specimens. For specimens that were positive for M. tuberculosis by MTBDR-Plus, the sensitivity and specificity for rifampin resistance were 91.7% and 96.6%, respectively, and for isoniazid (INH) they were 70.6% and 99.1%. The Direct LPA had a sensitivity of 88.4% and a specificity of 94.6% for M. tuberculosis detection, with a sensitivity of 72.5% in smear-negative specimens. Ten of 639 MGIT cultures grew Mycobacterium avium complex or Mycobacterium kansasii, half of which were detected by Direct LPA. Both LPA assays performed well in specimens from HIV-infected individuals, including in AFB smear-negative specimens, with 72.5% sensitivity for M. tuberculosis identification with the Direct LPA and 44.1% sensitivity with MTBDR-Plus. LPAs have a continued role for use in settings where rapid identification of INH resistance and clinically relevant NTM are priorities.
Share